We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-1.74%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.74B
AUM Growth
+$339M
Cap. Flow
-$310M
Cap. Flow %
-11.3%
Top 10 Hldgs %
45.15%
Holding
404
New
120
Increased
93
Reduced
80
Closed
88

Top Buys

Rank Stock Value
1
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$23.4M
2
XOM icon
ExxonMobil
XOM
+$15.3M
3
PXD
Pioneer Natural Resource Co.
PXD
+$12.1M
4
MRK icon
Merck
MRK
+$9.03M
5
BPMC
Blueprint Medicines
BPMC
+$8.62M

Top Sells

Rank Stock Value
1
TPST icon
Tempest Therapeutics
TPST
+$53.9M
2
AGN
Allergan plc
AGN
+$33.8M
3
IWM icon
iShares Russell 2000 ETF
IWM
+$24.7M
4
MBLY
Mobileye N.V.
MBLY
+$7.21M
5
MNKD icon
MannKind Corp
MNKD
+$5.7M

Sector Composition

Rank Sector Weight
1 Healthcare 8.27%
2 Energy 1.27%
3 Technology 0.21%
4 Communication Services 0.15%
5 Industrials 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGN
376
DELISTED
Allergan plc
AGN
– –
-113,566
Closed -$33.8M
AGN
377
PUT
DELISTED
Allergan plc
AGN
– –
-505
Closed -$15M
ALDR
378
DELISTED
Alder Biopharmaceuticals
ALDR
– –
-46,800
Closed -$1.35M
HZNP
379
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-2,429
Closed -$6.31M
IPCI
380
DELISTED
Intellipharmaceuticals International Inc.
IPCI
– –
-1,990
Closed -$60.1K
NXTM
381
CALL
DELISTED
NxStage Medical Inc.
NXTM
– –
-1,703
Closed -$2.95M
KERX
382
DELISTED
Keryx Biopharmaceuticals Inc
KERX
– –
-14,758
Closed -$158K
CASC
383
DELISTED
Cascadian Therapeutics, Inc.
CASC
– –
-69,659
Closed -$681K
CEMP
384
PUT
DELISTED
Cempra, Inc.
CEMP
– –
-517
Closed -$1.77M
HTWR
385
PUT
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
– –
-133
Closed -$1.17M
KYTH
386
PUT
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
– –
-188
Closed -$943K
GEVA
387
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
– –
-3,013
Closed -$294K
GEVA
388
PUT
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
– –
-54
Closed -$527K
PCYC
389
CALL
DELISTED
PHARMACYCLICS INC
PCYC
– –
-186
Closed -$4.76M
PCYC
390
PUT
DELISTED
PHARMACYCLICS INC
PCYC
– –
-10
Closed -$256K
SLXP
391
CALL
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
– –
-4,554
Closed -$78.7M
DARA
392
DELISTED
DARA BIOSCIENCES INC COM STK (DE)
DARA
– –
-117,370
Closed -$86K
CTIC
393
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
– –
-33,163
Closed -$640K
RXII
394
DELISTED
GALENA BIOPHARMA INC COM
RXII
– –
-3,436,456
Closed -$4.78M
CELG
395
DELISTED
Celgene Corp
CELG
– –
-22,225
Closed -$2.56M
CELG
396
PUT
DELISTED
Celgene Corp
CELG
– –
-478
Closed -$5.51M
12 13 14 15
16

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2015 Portfolio in Review

As of Q2 2015, Sabby Management held 404 positions worth $2.74B, up 14% from $2.4B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sabby Management withdrew a net $310M in Q2 2015, closing 88 positions and reducing 80 holdings. Its most notable exit was Allergan plc, an estimated $33.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 8.3% of assets, down from 9.4% a quarter earlier, followed by Energy and Technology.

Against the trend, Sabby Management opened a new position in ExxonMobil worth $14.8M.

  • Sabby Management's largest Q2 2015 buy was ExxonMobil: 178,310 shares worth $14.8M.
  • Sabby Management added most to iShares 20+ Year Treasury Bond ETF in Q2 2015, an estimated $23.4M increase.
  • Sabby Management's biggest Q2 2015 reduction was Tempest Therapeutics, cutting an estimated $53.9M.
  • Sabby Management fully exited Allergan plc in Q2 2015, selling an estimated $33.8M.
  • Sabby Management's ten largest holdings make up 45% of its $2.74B portfolio in Q2 2015.
  • Sabby Management opened 120 new positions and closed 88 in Q2 2015.
  • Sabby Management's portfolio value rose 14% quarter-over-quarter to $2.74B.

Based on Sabby Management's 13F filing for Q2 2015, filed 14 Aug 2015.